SCHEMBL30312968

SCHEMBL30312968

CC(C)(C)OC(=O)N1CCC2(CC1)C(=O)Nc1cc(Br)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
ALK Q9UM73 1/20 0.40
USP30 Q70CQ3 1/20 0.40
NR1H2 P55055 4/20 0.40
BACE1 P56817 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
NOTCH1 P46531 2/20 0.40
RXRA P19793 2/20 0.39
NR1H3 Q13133 2/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
GSK3B P49841 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
ADRA2B P18089 1/20 0.39
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39
ESRRB O95718 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1233346 1.00 GPR119 (0.41) GPR119ALKUSP30NR1H2BACE1
SCHEMBL30507206 0.91 ADRA2B (0.47) GPR119ALKUSP30NR1H2BACE1
SCHEMBL13310616 0.91 ADRA2B (0.47) GPR119ALKUSP30NR1H2BACE1
SCHEMBL23648712 0.86 HDAC2 (0.45) NR1H2KDM4EMAPTTHRBRXRA
SCHEMBL17584776 0.84 ADRA2B (0.44) USP30NR1H2RXRANR1H3CCNB2
SCHEMBL26225770 0.84 MAPT (0.46) NR1H2KDM4EMAPTTHRBNOTCH1
SCHEMBL1195957 0.83 NR1H2 (0.51) GPR119NR1H2BACE1RXRANR1H3
SCHEMBL1195959 0.83 NR1H2 (0.51) GPR119NR1H2BACE1RXRANR1H3
SCHEMBL23594971 0.82 CCNB2 (0.42) GPR119ALKUSP30BACE1KDM4E
SCHEMBL2075657 0.82 IP6K1 (0.46) ADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950682-B1 PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) 2026-02-11 EP disclosed
US-12473298-B2 Amide compounds, preparation method therefor, and use thereof in the medical field SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) 2025-11-18 US disclosed
US-12466829-B2 Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2025-11-11 US disclosed
CN-113330008-B Preparation method of amide compound and application of amide compound in medicine field 上海华汇拓医药科技有限公司 2024-05-07 CN disclosed
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-04-27 US disclosed
EP-4146660-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2023-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466829-B2 Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC2R, MC1R, MC3R GPR119 93/4885ALK 4391/4885USP30 4015/4885
US-12473298-B2 Amide compounds, preparation method therefor, and use thereof in the medical field EZH2, IKZF2, EZH1 GPR119 2804/4885ALK 2245/4885USP30 1669/4885
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC2R, MC1R, MC3R GPR119 93/4885ALK 4391/4885USP30 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.